The animal origin-free (AOF) trend in bioprocessing has taken a while to reach microbial bioproduction. In this podcast, we explore the reasons behind this and delve into how AOF products are impacting the future of biopharmaceutical manufacturing. We also discuss the first chemically defined microbial medium—the Gibco™ Bacto™ CD Supreme Fermentation Production Medium (FPM). Hydrolysate-free and AOF, this dry powder medium was specially designed to support high-cell-density cultures of E. Coli. Listen to bioprocessing experts and discover more.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.